(Q48630386)

13 February 2018

title

[Update: Behçet's disease]. (English)

1 reference

13 February 2018

0 references

1

1 reference

13 February 2018

language of work or name

German

0 references

publication date

1 November 2012

1 reference

13 February 2018

number of pages

5

1 reference

Zeitschrift fuer Rheumatologie

inferred from page(s)

published in

1 reference

13 February 2018

volume

71

1 reference

13 February 2018

issue

9

1 reference

13 February 2018

page(s)

760-764

1 reference

13 February 2018

https://scigraph.springernature.com/pub.10.1007/s00393-012-0984-x

exact match

0 references

cites work

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Resistant Behçet disease responsive to anakinra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Diagnostic value of pathergy test in Behcet's disease according to the change of incidence over the time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Gender influence on ocular manifestations and their outcome in Behcet's Disease. A long-term follow-up of up to 20 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Expression of Pro-inflammatory Protein S100A12 (EN-RAGE) in Behçet's Disease and Its Association with Disease Activity: A Pilot Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

EULAR recommendations for the management of Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Replication of a microsatellite genome-wide association study of Behcet's disease in a Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Ocular involvement is associated with HLA-B51 in Adamantiades-Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Behçet's syndrome with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Serum interleukin-18 levels in patients with Behçet's disease. Is its expression associated with disease activity or clinical presentations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

The 2009 prospective multi-center epidemiologic survey of uveitis in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Adalimumab for the treatment of Behçet's disease: experience in 19 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Mortality in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Excessive CD4+ T cells co-expressing interleukin-17 and interferon-γ in patients with Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

TNF polymorphisms in patients with Behçet disease: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Differences in clinical manifestations, treatment, and concordance rates with two major sets of criteria for Behçet's syndrome for patients in the US and Japan: data from a large, three-center cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00393-012-0984-X

Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease

21 January 2018

1 reference

12 December 2020

Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study

1 reference

12 December 2020

Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease

1 reference

12 December 2020

IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behcet's disease

1 reference

12 December 2020

Increased enthesopathy among Behçet's syndrome patients with acne and arthritis: an ultrasonography study

1 reference

12 December 2020

Successful use of canakinumab in a patient with resistant Behçet's disease

1 reference

12 December 2020

Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease

1 reference

12 December 2020

[Revised diagnostic criteria for Behçet's disease in 1987]

1 reference

12 December 2020

Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab

1 reference

12 December 2020

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

1 reference

12 December 2020

Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab

1 reference

12 December 2020

Production of interleukin-17 in Behcet's disease is inhibited by cyclosporin A.

1 reference

12 December 2020

Th17 cells in Behçet's disease: a new immunoregulatory axis.

1 reference

12 December 2020

Behçet's disease and genes within the major histocompatibility complex region

1 reference

12 December 2020

Genome-wide pathway analysis of a genome-wide association study on psoriasis and Behcet's disease

1 reference

12 December 2020

Tocilizumab treatment for neuro-Behcet's disease, the first report

1 reference

12 December 2020

Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment

1 reference

12 December 2020

Genome-wide association studies in Behçet's disease: expectations and promises

1 reference

12 December 2020

A possible decline in the incidence and severity of Behçet's disease: implications for an infectious etiology and oral health

1 reference

12 December 2020

IL-17A has an important role in the acute attacks of Behçet's disease

1 reference

12 December 2020

10.1007/S00393-012-0984-X

Identifiers

DOI

1 reference

13 February 2018

PubMed ID

23138553

1 reference

13 February 2018